Eisai Inc. - Strategic SWOT Analysis Review

Date: May 3, 2016
Pages: 34
Price:
US$ 125.00
License [?]:
Publisher: GlobalData
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: E6C86BCB691EN
Leaflet:

Download PDF Leaflet

Eisai Inc. - Strategic SWOT Analysis Review
Eisai Inc. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services.

This up-to-the-minute company report will help you to formulate strategies to drive your business by enabling you to understand your partners, customers and competitors better.

Scope
  • Business description – A detailed description of the company’s operations and business divisions. - Corporate strategy – GlobalData’s summarization of the company’s business strategy.
  • SWOT analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history – Progression of key events associated with the company.
  • Major products and services – A list of major products, services and brands of the company.
  • Key competitors – A list of key competitors to the company.
  • Key employees – A list of the key executives of the company.
  • Executive biographies – A brief summary of the executives’ employment history.
  • Key operational heads – A list of personnel heading key departments/functions.
  • Important locations and subsidiaries – A list of key locations and subsidiaries of the company, including contact details.
  • Key manufacturing facilities – A list of key manufacturing facilities of the company.
Highlights

Eisai Inc. (Eisai) is a healthcare company, which focuses on the discovery, development and marketing of pharmaceutical products. The company's major products include Aricept for Alzheimer’s treatment, Aciphex for acid reflux, Akynzeo for nausea and vomiting dring the course of cancer chemotherapy, Aloxi anti-nausea medication injection, Banzel for adjunctive treatment and Panretin for the treatment of skin lesions in AIDS-related Kaposi's sarcoma. The company’s research and development activities focus on therapeutic areas such as neuroscience; cancer, antibody-based programs; vascular, inflammatory and immunological reaction. Eisai established partnerships and collaborations with global companies such as Pfizer Inc., Janssen Pharmaceutica Inc., and Elan Pharma International Limited and Elan Pharmaceutical Inc for the development and distribution of drugs. The company is a subsidiary of Eisai Co., Ltd. and is headquartered in New Jersey, the US.

Eisai Inc. Key Recent Developments

Apr 20, 2016: Dr. Avinash Desai appointed Vice President, Americas Oncology Medical Affairs, Oncology Business Group at Eisai
Apr 11, 2016: Beyhan Zaim appointed Vice President Commercial Development & Alzheimer's Disease Global Lead, Neurology Business Group at Eisai
Apr 06, 2016: Paul Hawthorne appointed Senior Vice President, U.S. Commercial, Neurology Business Group at Eisai
Mar 30, 2016: Global Drug Maker Eisai Signs Three-Year Contract Extension For CSC’s Total Regulatory Solution as-a-Service
Oct 28, 2015: BVGH Accelerates R&D for Neglected Diseases through WIPO Re:Search Collaborations

Reasons to Buy
  • Gain key insights into the company for academic or business research purposes. Key elements such as SWOT analysis and corporate strategy are incorporated in the profile to assist your academic or business research needs.
  • Identify potential customers and suppliers with this report’s analysis of the company’s business structure, operations, major products and services and business strategy.
  • Understand and respond to your competitors’ business structure and strategies with GlobalData’s detailed SWOT analysis. In this, the company’s core strengths, weaknesses, opportunities and threats are analyzed, providing you with an up to date objective view of the company.
  • Examine potential investment and acquisition targets with this report’s detailed insight into the company’s strategic, business and operational performance.
Note: Some sections may be missing if data is unavailable for the company.
SECTION 1 - ABOUT THE COMPANY

Eisai Inc. - Key Facts
Eisai Inc. - Key Employees
Eisai Inc. - Key Employee Biographies
Eisai Inc. - Major Products and Services
Eisai Inc. - History
Eisai Inc. - Company Statement
Eisai Inc. - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries

SECTION 2 – COMPANY ANALYSIS

Eisai Inc. - Business Description
Eisai Inc. - Corporate Strategy
Eisai Inc. - SWOT Analysis
SWOT Analysis - Overview
Eisai Inc. - Strengths
Strength - Strong In-house Research Expertise
Strength - Product Collaboration with Leading Players
Strength - Marketed Products
Eisai Inc. - Weaknesses
Weakness - Weak Financial Performance
Eisai Inc. - Opportunities
Opportunity - Rising Healthcare Expenditure in the US
Opportunity - Strategic Initiatives
Opportunity - Strategic Partnerships
Opportunity - Orphan Drug Designation
Eisai Inc. - Threats
Threat - Intense Competition
Threat - Stringent Government Regulations
Threat - Litigation Claims
Eisai Inc. - Key Competitors

SECTION 3 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

Eisai Inc., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016
Eisai Inc., Pharmaceuticals & Healthcare, Deals By Type, 2010 to YTD 2016
Eisai Inc., Recent Deals Summary

SECTION 4 – COMPANY’S RECENT DEVELOPMENTS

Apr 20, 2016: Dr. Avinash Desai appointed Vice President, Americas Oncology Medical Affairs, Oncology Business Group at Eisai
Apr 11, 2016: Beyhan Zaim appointed Vice President Commercial Development & Alzheimer's Disease Global Lead, Neurology Business Group at Eisai
Apr 06, 2016: Paul Hawthorne appointed Senior Vice President, U.S. Commercial, Neurology Business Group at Eisai
Mar 30, 2016: Global Drug Maker Eisai Signs Three-Year Contract Extension For CSC’s Total Regulatory Solution as-a-Service
Oct 28, 2015: BVGH Accelerates R&D for Neglected Diseases through WIPO Re:Search Collaborations
Jul 16, 2015: Eisai Enters Agreement to Transfer Its Research Triangle Park Campus to Biogen
Jun 01, 2015: Ivor Macleod Appointed Senior Vice President, Chief Financial Officer and Chief Compliance Officer of Eisai
Apr 09, 2015: Eisai Realigns U.S. Operations

SECTION 5 – APPENDIX

Methodology
About GlobalData
Contact Us
Disclaimer

LIST OF TABLES

Eisai Inc., Key Facts
Eisai Inc., Key Employees
Eisai Inc., Key Employee Biographies
Eisai Inc., Major Products and Services
Eisai Inc., History
Eisai Inc., Other Locations
Eisai Inc., Subsidiaries
Eisai Inc., Key Competitors
Eisai Inc., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016
Eisai Inc., Pharmaceuticals & Healthcare, Deals By Type, 2010 to YTD 2016
Eisai Inc., Recent Deals Summary

LIST OF FIGURES

Eisai Inc., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016
Eisai Inc., Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016
Skip to top


Ask Your Question

Eisai Inc. - Strategic SWOT Analysis Review
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: